Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
One Biosciences leverages single-cell technologies to identify new therapeutics for difficult-to-treat diseases.
Bios Life develops AI-enabled cancer surveillance and personalized virtual care services.
Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.
Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.
Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
Ovid Therapeutic's purpose is to solve intractable medical problems.
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Redmile Group has invested in 106 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Redmile Group's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 15 different industry categories.
Among tracked funding rounds, Oruka Therapeutics received $700.4M in a Post-IPO Equity round. Redmile Group's total known invested capital is $12.8B.
Redmile Group's average investment size is $120.9M across its portfolio of 106 companies.
Recent Redmile Group portfolio additions include Star Therapeutics, ADC Therapeutics, One Biosciences, Bios Life, Annexon Biosciences. These companies were founded in 2020 or later.